DOCSLIB.ORG

Our Probiotic Strains Str Ou Ainsr Or Pr S Tobioic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Our Probiotic Strains Str Ou Ainsr Or Pr S Tobioic THERAPEUTIC IndEx GAStroenteroloGy pag. 5 OUROUR PROBIOTICPROOBIOTTIC ImmunoloGy pag. 17 DermAtoloGy pag. 21 STRAINSSTRRAINSS AntI-AGInG pag. 23 CArDIoloGy/ metAbolISm pag. 27 DIetetICS pag. 29 GIneColoGy pag. 31 uroloGy pag. 39 Gut-brAIn pag. 43 Probiotics like nobody else OurOur InnovativeInnovative orAl CAre pag. 47 Probiotical S.p.A. Via E. Mattei, 3, 28100 Novara (NO), Italy - T: +39 0321 46 59 33 61 Strains:Sttrains:i F: +39 0321 49 26 93 - email: [email protected] - www.probiotical.com teChnoloGIeS pag. 49 ReadyReaddy forfor YourYour HealthHeallth tHeraPeUtiC index GastroenteroloGy pag. 5 ImmunoloGy pag. 17 DermatoloGy pag. 20 antI-aGInG pag. 22 CarDIoloGy/metabolIsm pag. 25 DIetetICs pag. 27 GIneColoGy pag. 29 uroloGy pag. 37 Gut-braIn pag. 41 oral Care pag. 44 teChnoloGIes pag. 45 Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 1 Probiotical is driving probiotics innovation since 1985. Our expertise comprises strain selection, advanced R&D, production of strains to finished products with all guarantees of stability and demonstrated efficacy in many functionalities. Our strains can be proposed in allergen-free quality, microencapsulated, and standardized in different concentrations. Strains available as raw material can be provided in bulk or as customized finished products. Strains available as finished dosage form can be provided only as Probiotical finished products. Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 3 StrainS & blendS index Bifidobacterium • Bifidobacterium breve - BR03™ (DSM 16604) Gastroenterology: Strain: pag. 8, 15 - Blend: pag. 5, 6, 8, 10, 14 ; Dermatology: Blend: pag. 21 ; Dietetics: Strain: pag. 27 - Blend: pag. 27 ; • Bifidobacterium adolescentis - BA02 (DSM 18351, formerly Urology: Strain: pag. 35, 38 ; Gut-brain : Strain: pag 42 - Blend: pag 43 ALB 1) Gastroenterology: Blend: pag. 8 • Bifidobacterium breve - B632™ (DSM 24706) • Bifidobacterium animalis subsp. lactis - BA05 Gastroenterology: Blend : pag. 5, 6 ; Immunology: Blend : pag. 19 ; (DSM 18352) Gynecology: Strain: pag. 35 Urology: Strain: pag. 38 • Bifidobacterium animalis subsp. lactis - Bb1 • Bifidobacterium breve - MB113 (DSM 23732) (DSM 17850) Anti-aging: Strain: pag. 23 ; Gynecology: Cardiology/metabolism: Strain: pag 25 - Blend: pag 25 Strain: pag. 35 ; Urology: Strain: pag. 39, 40 • Bifidobacterium infantis - BI02 (DSM 24687, formerly MB287) Cardiology/metabolism: Strain: pag. 26 • Bifidobacterium animalis subsp. lactis - BS01™ (LMG P-21384) Gastroenterology: Strain: pag. 7 , • Bifidobacterium longum - W11 (LMG P-21586) Blend: pag. 8 , Immunology: Strain pag. 18 - Blend: pag. 17 ; Gastroenterology: Strain: pag. 9; Gut-brain : Strain: pag 43 Dermatology: Blend: pag. 20 ; Anti-aging: Strain: pag. 22 ; • - BL03 (DSM 16603) Gastroenterology: Gut-brain : Strain: pag. 42 - Blend: pag. 43 Bifidobacterium longum Blend: pag. 8 , Urology: Strain : pag. 40 ; Gut-brain : Blend: pag 43 • Bifidobacterium animalis subsp. lactis - BS05 • Bifidobacterium longum - 04 (DSM 23233) (DSM 23032) Anti-aging: Strain: pag. 22 Cardiology/metabolism: Blend: pag. 25 ; Dietetics: Strain: pag. 28 ; Gut-brain : Blend: pag. 41 • Bifidobacterium animalis subsp. lactis - BS07 (MB 2409) Cardiology/metabolism: Strain: pag. 25 • Bifidobacterium longum - DLBL07 (DSM25669) Anti-aging: Blend: pag. 24 • Bifidobacterium animalis subsp. lactis - MB2409 (DSM 23733) Cardiology/metabolism: Blend: pag. 25 • Bifidobacterium longum - DLBL08 (DSM 25670) Anti-aging: Blend: pag. 24 • Bifidobacterium bifidum - BB01 (DSM 22892) Gastroenterology: Strain: pag. 13 • Bifidobacterium longum - DLBL09 (DSM 25671) Anti-aging: Blend: pag. 24 • Bifidobacterium bifidum - BB06 (MB 107) • Bifidobacterium longum - DLBL10 (DSM 25672) Cardiology/metabolism: Strain: pag. 25 Anti-aging: Blend: pag. 24 • Bifidobacterium bifidum - MB109 (DSM 23731) • Bifidobacterium longum - DLBL11 (DSM 25673) Cardiology/metabolism: Strain: pag. 25 - Blend: pag. 25 Anti-aging: Blend: pag. 25 Lactobacillus • Limosilactobacillus fermentum - LF5 (CNCM I-789) (API) (formerly Lactobacillus fermentum ) Gastroenterology: Strain: pag. 16 ; Gynecology: Strain: pag. 29, 34 • Lactobacillus acidophilus - LA02 (DSM 21717) Gastroenterology: Strain: pag. 13, 15 - Blend: pag. 10 ; • Limosilactobacillus fermentum - LF08 (DSM 18297) Gynecology: Blend: pag. 31 ; Urology: Strain: pag. 38 ; (formerly Lactobacillus fermentum ) Gynecology: Strain: pag. 29 Gut-brain : Strain: pag 40, 42 • Limosilactobacillus fermentum - LF09 (DSM 18298) • Lactobacillus acidophilus - LA06 (DSM 23033) (formerly Lactobacillus fermentum ) Gastroenterology : Strain: pag. 16 ; Gynecology: Strain: pag. 29 Anti-aging: Strain: pag. 22 • Lactobacillus acidophilus - CRL1294 (DSM 24513) • Limosilactobacillus fermentum - LF10 (DSM 19187) (formerly Lactobacillus fermentum ) Gastroenterology : Strain: pag. 16 ; (under worldwide exclusive license from the CERELA) Gynecology: Strain: pag. 30 - Blend: pag. 31, 34 ; Gut-brain : Blend: pag. 42 Gynecology: Strain: pag. 31 • Limosilactobacillus fermentum - LF11 (DSM 19188) • - LC03 (DSM 27537) Lacticaseibacillus casei (formerly Lactobacillus fermentum ) Gastroenterology : Strain: pag. 16 ; (formerly Lactobacillus casei ) Gynecology: Strain: pag. 30 Gastroenterology: Strain: pag. 13 • Limosilactobacillus fermentum - LF15 (DSM 26955) • Lactobacillus crispatus - LCR01 (DSM 24619) (formerly Lactobacillus fermentum ) Gynecology: Blend: pag. 34 Gynecology: Strain: pag. 36 • Limosilactobacillus fermentum - LF16 (DSM 26856) • Lactobacillus crispatus - CRL1251 (DSM 24438) (formerly Lactobacillus fermentum ) Gynecology: Strain: pag. 30 ; (under worldwide exclusive license from the CERELA) Gut-brain : Blend: pag. 41 Gynecology: Strain: pag. 33 • Limosilactobacillus fermentum - ME-3 (DSM 14241) • Lactobacillus crispatus - CRL1266 (DSM 24439) (formerly Lactobacillus fermentum ) Cardiology/metabolism: Strain: pag. 26 (under worldwide exclusive license from the CERELA) • Lactobacillus gasseri - LGS06 (DSM 32405) Gynecology: Strain: pag. 33 Dietetics: Strain: pag. 28 ; Gynecology: Strain: pag. 36 • Lactobacillus delbrueckii subsp. bulgaricus - LDB01 • Lactobacillus gasseri - CRL1259 (DSM 24512) (DSM 16606) Gastroenterology : Strain: pag. 13 (under worldwide exclusive license from the CERELA) • Lactobacillus delbrueckii subsp. delbrueckii - LDD01 Gynecology: Strain: pag. 33 (DSM 22106) Gastroenterology : Strain: pag. 5 , 14 - Blend: pag. 6,12 ; • Lacticaseibacillus paracasei - LPC00 (LMG P-21380) Urology: Strain: pag. 38 ; Gut-brain : Blend: pag. 42 ; (formerly Lactobacillus paracasei ) Gastroenterology : Strain: pag. 13 ; Oral care : Blend: pag. 44 Immunology: Blend: pag. 19 • Limosilactobacillus fermentum - LF5 (CNCM I-789) • Lacticaseibacillus paracasei - LPC09 (DSM 24243) (formerly Lactobacillus fermentum ) (formerly Lactobacillus paracasei ) Gastroenterology : Strain: pag. 15 ; Gastroenterology : Strain: pag. 16 ; Gynecology: Strain: pag. 29, 34 Urology: Strain: pag. 28 - Blend: pag. 37 , 39 Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 5 • Lacticaseibacillus paracasei subsp. paracasei - • Lacticaseibacillus rhamnosus - LR05 (DSM 19739) CRL1289 (DSM 24440) (formerly Lactobacillus paracasei ) (formerly Lactobacillus rhamnosus ) (under worldwide exclusive license from the CERELA) Immunology: Blend: pag. 17 ; Dermatology: Blend: pag. 20 Gynecology: Strain: pag. 33 • Lacticaseibacillus rhamnosus - LR06 (DSM 21981) • Lactiplantibacilluspentosus - LPS01 (DSM 21980) (formerly Lactobacillus rhamnosus ) (formerly Lactobacillus pentosus ) Gastroenterology : Strain: pag. 14 - Blend: pag. 12 ; Urology: Gastroenterology : Strain: pag. 14 - Blend: pag. 12 ; Anti-aging: Strain: pag. 37 ; Oral care : Blend: pag. 44 Strain: pag. 22 ; Urology: Strain: pag. 35 ; Gut-brain : Blend: pag 41 - Strain: pag. 42 ; Oral care : Blend: pag. 44 • Lactiplantibacillus plantarum - LP01™ (LMG P-21021) (formerly Lactobacillus plantarum ) Gastroenterology : Strain: pag. 7, • Lactobacillus salivarius - CRL1328 (DSM 24441) 14, 15 - Blend: pag. 6, 8, 10, 12 ; Immunology: Blend: pag. 17, 19 ; (under worldwide exclusive license from the CEntro Anti-aging: Strain : pag. 22 ; Gynecology: Blend: pag. 34 ; Urology: de REferencia para LActobacilos, Argentina) Strain: pag. 40 - Blend: pag. 37, 40 ; Gut-brain : Strain: pag. 42 - Gastroenterology : Strain : pag.16 ; Gynecology: Strain: pag. 31 ; Blend: pag. 41, 42 ; Oral care : Blend: pag. 44 Urology: Strain: pag. 38 • Lactiplantibacillus plantarum - LP02 (LMG P-21020) (formerly Lactobacillus plantarum ) • Lactobacillus salivarius - LS01™ (DSM 22775) Gastroenterology : Strain: pag. 14 ; Immunology: Blend: pag. 17 ; Gastroenterology: Strain: pag. 15 ; Immunology: Blend: pag. 19 ; Gynecology: Blend: pag. 34 ; Urology: Strain: pag. 37 Dermatology: Strain: pag. 20 - Blend: pag. 21 ; Anti-aging: Strain: pag. 22 ; Gut-brain : Strain: pag. 42 • Lactiplantibacillus plantarum - LP09 (DSM 25710) (formerly Lactobacillus plantarum ) Gastroenterology : Strain: pag. 14 • Lactobacillus salivarius - LS03 (DSM 22776) • Limosilactobacillus reuteri - Lb26 (DSM 16341) Dermatology: Strain: pag. 21 ; Gut-brain : Blend: pag 42 (formerly Lactobacillus reuteri ) Anti-aging: Strain: pag. 23 ; Urology: • Lactococcus lactis - LLC02 (DSM 29536) Strain: pag. 39 Gastroenterology: Blend: pag. 6 • Limosilactobacillus reuteri - LRE02 (DSM 23878) (formerly Lactobacillus reuteri ) Gastroenterology : Strain: pag. 15 , Immunology: Strain: pag. 18 ; Gynecology: Strain: pag. 35 ; Urology: Strain: pag. 40 Streptococcus •
Load more

Recommended publications
  • Bifidobacterium Response to Lactulose Ingestion in the Gut Relies on A
    ARTICLE https://doi.org/10.1038/s42003-021-02072-7 OPEN Bifidobacterium response to lactulose ingestion in the gut relies on a solute-binding protein- dependent ABC transporter ✉ Keisuke Yoshida 1 , Rika Hirano2,3, Yohei Sakai4, Moonhak Choi5, Mikiyasu Sakanaka 5,6, Shin Kurihara3,6, Hisakazu Iino7, Jin-zhong Xiao 1, Takane Katayama5,6 & Toshitaka Odamaki1 This study aims to understand the mechanistic basis underlying the response of Bifido- bacterium to lactulose ingestion in guts of healthy Japanese subjects, with specific focus on a lactulose transporter. An in vitro assay using mutant strains of Bifidobacterium longum subsp. 1234567890():,; longum 105-A shows that a solute-binding protein with locus tag number BL105A_0502 (termed LT-SBP) is primarily involved in lactulose uptake. By quantifying faecal abundance of LT-SBP orthologues, which is defined by phylogenetic analysis, we find that subjects with 107 to 109 copies of the genes per gram of faeces before lactulose ingestion show a marked increase in Bifidobacterium after ingestion, suggesting the presence of thresholds between responders and non-responders to lactulose. These results help predict the prebiotics- responder and non-responder status and provide an insight into clinical interventions that test the efficacy of prebiotics. 1 Next Generation Science Institute, RD Division, Morinaga Milk Industry Co., Ltd., Zama, Japan. 2 Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Nonoichi, Japan. 3 Biology-Oriented Science and Technology, Kindai University, Kinokawa, Japan. 4 Food Ingredients and Technology Institute, RD Division, Morinaga Milk Industry Co., Ltd, Zama, Japan. 5 Graduate School of Biostudies, Kyoto University, Kyoto, Japan. 6 Faculty of Bioresources and Environmental Sciences, Ishikawa Prefectural University, Nonoichi, Japan.
    [Show full text]
  • Recursos Naturales - Referencias Bibliográficas
    Recursos Naturales - Referencias Bibliográficas Nombre Nombre # Referencia Común Científico Afsar Shaik; Rupesh S Kanhere; Rajaram Cuddapah; Nelson Kumar S; Artemisa, Artemisia Prasanth Reddy Vara; Saisaran Sibyala. Antifertility activity of Artemisia 1 Mugwort vulgaris L. vulgaris leaves on female Wistar rats. Chinese Journal of Natural Medicines 2014, 12(3): 0180-0185 Diandra Araújo Luz, Alana Miranda Pinheiro; Mallone Lopes Silva; Marta Chagas Monteiro; Rui Daniel Prediger; Cristiane Socorro Ferraz Maia; Petiveria 2 Anamú Enéas Andrade Fontes-Júnior. Ethnobotany, phytochemistry and alliacea L. neuropharmacological effects of Petiveria alliacea L. (Phytolaccaceae): A review. Journal of Ethnopharmacology 185 (2016) 182–201 Plantago B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 4° 3 Llantén major L. Edición. p334-335 Turnera B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 3° 4 Damiana diffusa Wild. Edición. p178-179. var. Aesculus Castaño de B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 3° 5 hippocastanu Indias Edición. p172-175 m 1.- Chung-Hua Hsu & Col. The Mushroom Agaricus blazei Murill Extract Normalizes Liver Function in Patients with Chronic Hepatitis B. The Journal of Alternative and Complementary Medicine. Volume 14, Number 3, 2008, pp. 299–301 2.- Diogo G. Valadares, Mariana C. Duarte, Laura Ramírez, Miguel A. Chávez-Fumagalli, Eduardo A.F. Coelho. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis. Experimental Parasitology, Volume 132, Issue 2, October 2012, Pages 228-236 6 Setas Agaricus blazei 3.- Chung-Hua Hsu & Col. The Mushroom Agaricus blazei Murill in Combination with Metformin and Gliclazide Improves Insulin Resistance in Type 2 Diabetes: A Randomized, Double-Blinded, and Placebo- Controlled Clinical Trial.
    [Show full text]
  • Delivery of Metabolically Neuroactive Probiotics to the Human Gut
    International Journal of Molecular Sciences Article Delivery of Metabolically Neuroactive Probiotics to the Human Gut Peter A. Bron 1, Marta Catalayud 2 , Massimo Marzorati 2,3, Marco Pane 3, Ece Kartal 4 , Raja Dhir 1 and Gregor Reid 5,6,* 1 Seed Health, 2100 Abbot Kinney Blvd Suite G Venice, Los Angeles, CA 90291, USA; [email protected] (P.A.B.); [email protected] (R.D.) 2 ProDigest BV, Technologiepark-Zwijnaarde 94, 9052 Gent, Belgium; [email protected] (M.C.); [email protected] (M.M.) 3 Probioticial, Via Enrico Mattei 3, 28100 Novara, Italy; [email protected] 4 Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany; [email protected] 5 Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, 268 Grosvenor Street, London, ON N6A 4V2, Canada 6 Departments of Microbiology and Immunology, and Surgery, Western University, London, ON N6A 3K7, Canada * Correspondence: [email protected] Abstract: The human microbiome is a rich factory for metabolite production and emerging data has led to the concept that orally administered microbial strains can synthesize metabolites with neuroactive potential. Recent research from ex vivo and murine models suggests translational potential for microbes to regulate anxiety and depression through the gut-brain axis. However, so far, less emphasis has been placed on the selection of specific microbial strains known to produce the required key metabolites and the formulation in which microbial compositions are delivered to the Citation: Bron, P.A.; Catalayud, M.; gut. Here, we describe a double-capsule technology to deliver high numbers of metabolically active Marzorati, M.; Pane, M.; Kartal, E.; Dhir, R.; Reid, G.
    [Show full text]
  • PROBIOTICS, PREBIOTICS NEW FOODS, NUTRACEUTICALS and BOTANICALS for NUTRITION & HUMAN and MICROBIOTA HEALTH SCIENTIFIC ORGANISERS L
    rome - september 10/12, 2017 università urbaniana PROBIOTICS, PREBIOTICS NEW FOODS, NUTRACEUTICALS AND BOTANICALS for NUTRITION & HUMAN and MICROBIOTA HEALTH SCIENTIFIC ORGANISERS L. Capurso (Italy) A. Gasbarrini (Italy) A. Guarino (Italy) L. Morelli (Italy) INTERNATIONAL SCIENTIFIC COMMITTEE G. Barbara (Italy) R. Berni CananiPROBIOTICS, (Italy) PREBIOTICS P. Brigidi (Italy) M. L. Colombo NEW (Italy) FOODS, NUTRACEUTICALS AND BOTANICALS G. Delle Favefor NUTRITION(Italy) & HUMAN and MICROBIOTA HEALTH J. Dorè (France) V. Fogliano (The Netherlands) F. Guarner (Spain) M. Rescigno (Italy) H. Tilg (Austria) K. M. Tuohy (Italy) PEDIATRIC DAY A. Guarino (Italy) SCIENTIFIC REFEREES M. Anti (Italy) G. Capurso (Italy) M. Koch (Italy) UNDER THE PATRONAGE OF UNDER THE PATRONAGE OF Associazione Giovani Gastroenterologi ed Endoscopisti Italiani SIGE, Società Italiana di Gastroenterologia European Association for Gastroenterology, Endoscopy & Nutrition 5/7/2017 logo.JPG MTCC, Mediterranean Task Force for Cancer Control https://mail.google.com/mail/u/0/#inbox?projector=1 1/1 index Sunday, September 10 Aula Magna p. 8 Aula Élie Metchnikoff p. 11 Monday, September 11 Aula Magna p. 15 Aula Élie Metchnikoff p. 18 Tuesday, September 12 Aula Magna p. 20 Aula Élie Metchnikoff p. 22 Proceedings p. 27 Oral Communications p. 75 Posters p. 89 Faculty p. 126 Index of Authors p. 130 SCIENTIFIC PROGRAMME Abstract Authors Countries p. 133 General Information p. 134 Scientific Information p. 139 Exhibition Area p. 142 aula magna sunday, SEPTEMBER 10 sunday, SEPTEMBER 10 AULA magna 08.30-10.00 a.m. YOUNG ITALIAN GASTROENTEROLOGISTS (AGGEI) 02.00-03.00 p.m. OPENING CEREMONY MEET THE EXPERT: QUESTIONS AND ANSWERS Chairs: L.
    [Show full text]
  • Cosmeceutical Importance of Fermented Plant Extracts: a Short Review
    International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 10, Issue 4, 2018 Review Article COSMECEUTICAL IMPORTANCE OF FERMENTED PLANT EXTRACTS: A SHORT REVIEW BHAGAVATHI SUNDARAM SIVAMARUTHI, CHAIYAVAT CHAIYASUT, PERIYANAINA KESIKA * Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand Email: [email protected] Received: 30 Mar 2018, Revised and Accepted: 24 May 2018 ABSTRACT Personal care products, especially cosmetics, are regularly used all over the world. The used cosmetics are discharged continuously into the environment that affects the ecosystem and human well-being. The chemical and synthetic active compounds in the cosmetics cause some severe allergies and unwanted side effects to the customers. Currently, many customers are aware of the product composition, and they are stringent in product selection. So, cosmetic producers are keen to search for an alternative, and natural active principles for the development and improvisation of the cosmetic products to attain many customers. Phytochemicals are known for several pharmacological and cosmeceutical applications. Fermentation process improved the quality of the active phytochemicals and also facilitates the easy absorption of them by human system. Recently, several research groups are working on the cosmeceutical importance of fermented plant extracts (FPE), particularly on anti-ageing, anti-wrinkle, and whitening property of FPE. The current manuscript is presenting a brief
    [Show full text]
  • GRAS Notice 855, Bifidobacterium Animalis Subsp. Lactis Strain R0421
    GRAS Notice (GRN) No. 855 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory JHeimbach LLC April 3, 2019 Paulette Gaynor, Ph.D. Senior Regulatory Project Manager Division of Biotechnology and GRAS Notice Review (HFS-255) Office of Food Additive Safety Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740 Dear Dr. Gaynor: Pursuant to 21 CFR Part 170, Subpart E, Lallemand Health Solutions (Lallemand), through me as its agent, hereby provides notice of a claim that the addition to non-exempt milk-based term infant formula of Bifidobacteriurn anirnalis ssp. lactis strain R0421 is exempt from the premarket approval requirement of the Federal Food, Drug, and Cosmetic Act because Lallemand has determined that the intended use is generally recognized as safe (GRAS) based on scientific procedures. As required, one copy of the GRAS monograph and one signed copy of the statement of the Expert Panel are provided. Additionally, I have enclosed a virus-free CD-ROM with the GRAS monograph and the signed statement of the Expert Panel. If you have any questions regarding this notification, please feel free to contact me at 804-742-5543 o~ jheimbach.com. Si11~1/ ""James t. Heimbach, Ph.D., F.A.C.N. President Encl. ~~~~u~~lg) APR 8 2019 OFFICE OF 923 Water Street, P.O. Box 66, Port Royal Virginia 22535, USA FOOD ADDITl\/1: SAFETY tel. (+1) 804-742-5543 fax (+1) 202-478-0986 [email protected] LALLEMAND HEALTH SOLUTIONS Generally Recognized as Safe (GRAS) Determination for the Use of Bifidobacterium animalis subsp.
    [Show full text]
  • Tolerance and Safety of Lactobacillus Paracasei Ssp. Paracasei in Combination with Bifidobacterium Animalis Ssp
    Downloaded from British Journal of Nutrition (2009), 102, 869–875 doi:10.1017/S0007114509289069 q The Authors 2009 https://www.cambridge.org/core Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial . IP address: Arine M. Vlieger1*, Afke Robroch1, Stef van Buuren2,3, Jeroen Kiers4,5, Ger Rijkers6, 7 4 Marc A. Benninga and Rob te Biesebeke 170.106.202.8 1Department of Paediatrics, St Antonius Hospital, Nieuwegein, The Netherlands 2Department of Statistics, TNO Quality of Life, Leiden, The Netherlands 3 Department of Methodology and Statistics, FSS, University of Utrecht, The Netherlands , on 4 Global Development Centre, Friesland Foods, Leeuwarden, The Netherlands 26 Sep 2021 at 01:49:26 5NIZO, Ede, The Netherlands 6Department of Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands 7Department of Paediatric Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands (Received 11 September 2008 – Revised 29 January 2009 – Accepted 3 February 2009 – First published online 31 March 2009) , subject to the Cambridge Core terms of use, available at The addition of probiotics to infant formula has been shown to be an efficient way to increase the number of beneficial bacteria in the intestine in order to promote a gut flora resembling that of breast-fed infants. The objective of the present study was to evaluate the safety and tolerance of a combination of two probiotic strains in early infancy. A group of 126 newborns were randomised to receive a prebiotic-containing starter formula supplemented with Lactobacillus paracasei ssp. paracasei and Bifidobacterium animalis ssp.
    [Show full text]
  • The Pennsylvania State University the Graduate School Department
    The Pennsylvania State University The Graduate School Department of Food Science EFFECT OF STARCH SPHERULITES ON SURVIVAL OF BIFIDOBACTERIA IN THE PRESENCE OF ACID OR BILE A Thesis in Food Science by Srilatha Chittiprolu 2009 Srilatha Chittiprolu Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science May 2009 ii The thesis of Srilatha Chittiprolu was reviewed and approved* by the following: Robert F. Roberts Associate Professor of Food Science Thesis Advisor Stephen J. Knabel Professor of Food Science Gregory R. Ziegler Professor of Food Science John D. Floros Professor of Food Science Head of the Department of Food Science *Signatures are on file in the Graduate School iii ABSTRACT Probiotics are live microorganisms which have been shown to confer a health benefit on the host, when administered in sufficient amounts (FAO/WHO, 2001). Many of the probiotic bacteria currently used in foods and dietary supplements are members of Lactic Acid Bacteria. Strains of the genus Bifidobacterium are widely used as probiotics for human consumption. Bifidobacteria are often sensitive to stresses encountered during production and storage of food and during passage through the gastrointestinal tract. Thus, the overall purpose of this research was to determine if adhesion of bifidobacteria to starch-based spherulites can improve their survival when exposed to acid or bile. The first objective of this work was to develop a procedure to prepare spherulites in adequate quantities for use in adhesion and survival studies. Spherulites were prepared successfully in a Parr reactor (pressure vessel) using potato starch, high amylose maize starch (Hylon VII) and purified potato amylose.
    [Show full text]
  • Insight Into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1
    Viruses 2012, 4, 3179-3208; doi:10.3390/v4113179 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Insight into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1 E. M. Abdelwhab †,* and Hafez M. Hafez Institute of Poultry Diseases, Free Berlin University, Königsweg 63, 14163 Berlin, Germany; E-Mail: [email protected] † Present address: Molecular Pathogenesis and Ecology of Influenza Viruses Laboratory, Institute of Molecular Biology, Federal Research Institute for Animal Health, Friedrich Loeffler Institute, Isles of Riems, Suedufer 10, 17493 Greifswald, Germany * Author to whom correspondence should be addressed; E-Mails: [email protected]; [email protected]; Tel.: +49-30-8386-2679; +49-38-3517-1263; +49-38-3517-1237; Fax: +49-30-838-6267; +49-38-3517-1275. Received: 23 September 2012; in revised form: 4 November 2012 / Accepted: 8 November 2012 / Published: 19 November 2012 Abstract: Highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 causes a devastating disease in poultry but when it accidentally infects humans it can cause death. Therefore, decrease the incidence of H5N1 in humans needs to focus on prevention and control of poultry infections. Conventional control strategies in poultry based on surveillance, stamping out, movement restriction and enforcement of biosecurity measures did not prevent the virus spreading, particularly in developing countries. Several challenges limit efficiency of the vaccines to prevent outbreaks of HPAIV H5N1 in endemic countries. Alternative and complementary approaches to reduce the current burden of H5N1 epidemics in poultry should be encouraged. The use of antiviral chemotherapy and natural compounds, avian-cytokines, RNA interference, genetic breeding and/or development of transgenic poultry warrant further evaluation as integrated intervention strategies for control of HPAIV H5N1 in poultry.
    [Show full text]
  • HMF Immune Powder
    HMF Immune Powder Vitamins, minerals and probiotics Supplement Facts ‡ Serving Size 1 Sachet (5 g) targeting the immune system Servings Per Container 30 Amount Per Serving % DV • Helps to maintain immune and gastrointestinal health‡ Calories 10 Total Carbohydrate 2 g • Provides 15 billion CFU per dose from a combination of Total Sugars 1 g * five proprietary strains Includes 1 g Added Sugars 2%^ Vitamin C (as ascorbic acid/zinc ascorbate) 1000 mg 1111% • Includes 10 vitamins and seven minerals to help maintain good health‡ Vitamin D (as cholecalciferol) 25 mcg (1000 IU) 125% Thiamin (as thiamin hydrochloride) 0.6 mg 50% • Convenient, once-daily powder format Riboflavin (as riboflavin 5’-phosphate sodium) 0.65 mg 50% • Delicious, natural mixed berry flavor Niacin (as niacinamide) 8 mg 50% Vitamin B6 (as pyridoxine hydrochloride) 10 mg 588% Folate (as Metafolin® L-5-MTHF) 167 mcg DFE 42% (100 mcg L-5-MTHF) HMF Immune Powder combines 17 essential vitamins and minerals with Vitamin B12 (as hydroxocobalamin) 25 mcg 1042% five research-driven probiotic strains to support overall well-being, Biotin 25 mcg 83% gastrointestinal health and immune function. This blend offers zinc with Pantothenic Acid (as calcium d-pantothenate) 2.5 mg 50% Calcium (as calcium carbonate/tribasic calcium phosphate) 50 mg 4% vitamins C and D to support immune health by regulating the production Phosphorus (as tribasic calcium phosphate) 13 mg 1% and activity of immune cells. It also offers B vitamins to support Magnesium (as magnesium hydroxide/carbonate) 60 mg 14% energy metabolism, plus electrolytes to maintain good health. Notably, Zinc (as zinc ascorbate) 5.5 mg 50% Manganese (as manganese gluconate) 0.75 mg 33% approximately 80% of the body’s immunologically active cells are located Sodium (as sodium bicarbonate) 55 mg 2% in gut-associated lymphoid tissue, demonstrating an important interaction Potassium (as potassium bicarbonate/carbonate) 200 mg 4% between the intestines and the immune system.
    [Show full text]
  • UC San Diego UC San Diego Electronic Theses and Dissertations
    UC San Diego UC San Diego Electronic Theses and Dissertations Title Probiogenomic Analysis of Three Commonly Occuring Bifidobacterial Species Permalink https://escholarship.org/uc/item/8d67d715 Author Kim, Andrew Min Publication Date 2018 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA SAN DIEGO Probiogenomic Analysis of Three Commonly Occuring Bifidobacterial Species A Thesis submitted in partial satisfaction of the requirements for the degree Master of Science in Biology by Andrew Min Kim Committee in charge: Milton Saier, Chair Eric Allen, Co-Chair Stanley Lo 2018 © Copyright Andrew Min Kim, 2018 All rights reserved. The Thesis of Andrew Min Kim is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California San Diego 2018 iii TABLE OF CONTENTS Signature Page ........................................................................................................... iii Table of Contents ....................................................................................................... iv List of Tables ............................................................................................................. v Acknowledgements .................................................................................................... vi Abstract of the Thesis ................................................................................................ vii Introduction
    [Show full text]
  • Associations of Probiotic Fermented Milk (PFM) and Yogurt Consumption with Bifidobacterium and Lactobacillus Components of the Gut Microbiota in Healthy Adults
    nutrients Article Associations of Probiotic Fermented Milk (PFM) and Yogurt Consumption with Bifidobacterium and Lactobacillus Components of the Gut Microbiota in Healthy Adults Noemí Redondo-Useros, Alina Gheorghe, Ligia E. Díaz-Prieto, Brenda Villavisencio, Ascensión Marcos and Esther Nova * Immunonutrition Group, Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), Jose Antonio Novais, St.10., 28040 Madrid, Spain; [email protected] (N.R.-U.); [email protected] (A.G.); [email protected] (L.E.D.-P.); [email protected] (B.V.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +34-91-549-23-00 Received: 29 January 2019; Accepted: 12 March 2019; Published: 18 March 2019 Abstract: The current study investigates whether probiotic fermented milk (PFM) and yogurt consumption (YC) are related to both the ingested bacteria taxa and the overall gut microbiota (GM) composition in healthy adults. PFM and YC habits were analyzed in 260 subjects (51% male) by specific questionnaires, and the following groups were considered: (1) PFM groups: nonconsumers (PFM-NC, n = 175) and consumers (PFM, n = 85), divided as follows: Bifidobacterium-containing PFM (Bif-PFM; n = 33), Lactobacillus-containing PFM (Lb-PFM; n = 14), and mixed Bifidobacterium and Lactobacillus-containing PFM (Mixed-PFM; n = 38); (2) PFM-NC were classified as: yogurt nonconsumers (Y-NC; n = 40) and yogurt consumers (n = 135). GM was analyzed through 16S rRNA sequencing. PFM consumers showed higher Bifidobacteria taxa levels compared to NC, from phylum through to species. Specifically, Bif-PFM consumption was related to higher B.
    [Show full text]